Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Market Value $3,986,463 - a/o Dec 29, 2011 :))
Predict .025+ at market close.
Don't be surprised if we get a PR tomorrow ;)
A little patience fellows looking for substantial things to happen here soon :)
I feel like Allezoe is on the brink of something big and is being very hush hush....Is they create New HPV Diagnostic Technology that even slightly works this will pay off major. Sitting tight sure not going to miss this when a huge pr hits the wires.
http://www.allezoe.com/OurCompanies
Allezoe Medical Holdings is in the final stages of discussions to acquire:
* A company that has developed a breakthrough medical technology that will revolutionize the diagnosis and treatment of Human Papillomavirus (HPV), Bovine Papillomavirus (BPV), and potentially cervical cancer.
HPV is the most common sexually transmitted infection and most people who become infected do not know they have it, leading to further spread. Approximately 20 million Americans are infected with HPV — predictions are that 5.5 Million MORE will contract the HPV through sexual contact each year. There are more than 40 types of HPV that can infect the genital areas of both males and females.
The straightforward technology this company has fascinates us, particularly at a time when the number of women with cervical cancer (caused by HPV) is growing worldwide. Cervical cancer is currently the second most common cancer in women and is preventable with the right technologies and treatments.
* A company with state-of-the-art implant technologies for spinal surgery.
This company’s technology aims to facilitate spinal surgery and improve post-surgery quality of life for patients. As the senior population lives longer, and more opt for surgery to ease back pain, we hope to support options that offer them maximum comfort.
* A South Florida-based clinical trial research company.
Clinical trials are where great medical advancements are made, proven, and promoted to the next level. We are eager to be involved in seeing promising solutions to their logical next step.
Allezoe includes Organ Transport Systems, Inc. (OTS), a biomedical company engaged in developing, patenting, and commercializing portable hypothermic, oxygenated preservation and transport technology for human organs. OTS plans to redefine human organ transplantation through better preservation with its LifeCradle® product line.
Buyers in here PR must be brewing :)
Recap: Allezoe Medical Holdings (ALZM) Completes Exclusive Licensing Deal for HPV Diagnostic Technology
BOCA RATON, FLORIDA--(Marketwire - Dec. 20, 2011) - Allezoe Medical Holdings, Inc. (OTCBB:ALZM) announces that it has acquired the exclusive license to develop and market patent pending, advanced "see and treat" diagnostic technology for Human papillomavirus (HPV), the world's leading sexually transmitted infection (STI). An exclusive license has been signed by SureScreen Medical, Inc., a wholly-owned subsidiary of Allezoe, and AVM Corp., which recently acquired the technology and the pending patent application from its developer, Aequorea Vision Medical, Inc. Under the terms of the license, SureScreen will develop and market products worldwide using the technology in return for a fixed royalty to AVM, commencing on sales of products using the technology.
As a result of the license, Allezoe now holds the exclusive worldwide rights to this groundbreaking "see and treat" technology which will allow healthcare providers to identify cell damage from HPV instantaneously, bypassing the long lab wait times, fees and additional patient discomfort found in existing HPV diagnostic methods on the market, including the Pap smear.
With this license and the global marketing and distribution strategy it is developing, Allezoe will be positioned to enter its market. In the United States alone, there is a $6 billion annual diagnosis and treatment market for HPV, and the market is increasing under growing national attention to the virus. Recently, the Centers for Disease Control and Prevention has recommended the HPV vaccine be used for men as well. Allezoe's technology is a crucial counterpart to the vaccine, identifying any preexisting damage before vaccine administration; importantly, it also offers an important alternative for those who avoid the vaccine due to controversial side effects.
Infecting 233 million women worldwide, the virus is the leading cause of cervical cancer in women, which often results in death. HPV is known to cause a growing number of cancers and lesions in both genders, including cervical, neck, and throat cancer. More recently, HPV is being researched as a possible cause of heart disease. Allezoe's technology is a one-stop HPV solution for patients and their providers. Allezoe's HPV technology will be welcome in the United States, where healthcare costs are a growing concern. It has important implications for healthcare abroad and in poorer nations where patients do not have the luxury of making repeated visits to a clinic or waiting several days for a Pap smear report from a distant laboratory.
Allezoe CEO Michael Gelmon says, "This is not a virus we have the luxury of ignoring, when hundreds of millions of people around the world are affected and are further spreading the virus. Our new licensed technology offers the combination of accuracy plus efficiency. This is a large market that we are looking forward to penetrating, and we have a strategy in place so we can hit the ground running."
About Allezoe Medical Holdings
Allezoe Medical Holdings, Inc. (OTCBB:ALZM) is a holding company focused on acquiring the most high quality and in-demand medical products, solutions and services. Whether through diagnosis, treatment, or medical research itself, Allezoe is interested in companies that are making a striking difference in the healthcare system through technology and treatments for health issues that affect large populations. For more information, please visit www.allezoe.com.
Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk that could cause actual performance and results of operations to differ materially from those anticipated. These risks are set forth in the Company's most recently filed form 10-K and Form 10-Q reports. The Company assumes no obligation to update the statements contained in this release except as required by applicable securities disclosure rules. The Company's SEC filings are available at http://www.sec.gov.
late afternoon buyer sucking up shares, someone wants these shares, something big has to be brewing :)
Is Corey Ribotsky is going to the slammer will David Dalton be joining him?
Looking for .03+ close today and .05-.07ish by NYE.
Market Value1 --$3,778,474 --a/o Dec 23, 2011
this is extremely undervalued, expecting big things from Allezoe.
This should be back over .10
fully loaded sitting tight :)
coming developments will do wonders here, don't worry about the charts!
Looking forward to Tuesday, i am thinking good things coming our way :)
a little patience it's all coming together :)
a little patience it's all coming together :)
do whatever works for you. I am most likely unloading next week as this will just be a tax write off. I don't see any chance of ever recovering my losses from where I bought in at. All the best.
the O/S is very thin and most bigger pharma companies have a share structure around what Allezoe is.
Shares Outstanding 173,324,482 a/o Dec 02, 2011
March 30, 2011 this was $2.44 per share keep that in mind :) see you all tomorrow.
all these chart predictions will mean nada when the company kicks things in gear, sticking tight :)
flippers/day traders do your things... I'm sure not going to miss the big one and get left behind.
good luck.
do some DD on the most recent pr might be shocked what you find ;)
very highly doubt this will never see below .003 after tomorrow!
Share Structure
Market Value----$6,984,977----a/o Dec 21, 2011
Shares Outstanding----173,324,482----a/o Dec 02, 2011
Authorized Shares----500,000,000-----a/o Dec 01, 2010
Par Value---0.001
Market Value $6.9 Million with only 173 O/S. Exclusive deal in place signed by SureScreen Medical, Inc. Sticking tight this is going to get good in my opinion :)
Times are changing in a major way for this company and looking to be back to where we were 3 months ago very soon! For the flippers do whatever suites you but when this runs we will see who is left behind, not i ;)
we are at a point where those who bought in the .01's are realizing the real potential here. They sold and are now jumping back in, some will bash thinking they can get back in for a bargain price I highly don't see that happening. Expecting .05+ by tomorrow close and .07-.11 by mid Jan. Just my opinion locked and loaded :)
i know which way the company and future of this is going don't get ants in your pants, expecting major things here :)
you were saying the same thing at .001 .0005 now at .0001 bid pathetic.
very undervalued I see this back at .48 -.60+ in the near term big things going on. Patience :)
How can you buy lower then .0001?
there is obviously no interest in this so stop lying.
This is a complete mess.
bid: .0001 unreal and no bid on the way.. The Ribotsky/Dalton crew has cleaned house. I wonder if Dalton is going to the slammer with Ribotsky.
Univecinc.com phone number disconnected. Someone get in touch with DALTON this needs to stop.
David Dalton - Contact info.
Main: 410-486-1987
Cell: 443-253-0194
Univec site: 443-641-4449 (disconnected)
Email: univec@univecinc.com
Email: DLDHRI@AOL.COM
Email: Dalton@SpecialtyPharmacyServices.com
David Dalton - Contact info.
Main: 410-486-1987
Cell: 443-253-0194
Univec site: 443-641-4449
Email: univec@univecinc.com
Email: DLDHRI@AOL.COM
Email: Dalton@SpecialtyPharmacyServices.com
Office: Univec, Inc.
9722 Groffs Mill Dr. Suite 116
Owings Mills, Maryland 21117
or
38 Stags Leap ct. Gwynn Oak, Maryland
or
10 E Baltimore St. Baltimore MD 21202
http://www.umbiopark.com/biopark/park-leadership.aspx
http://www.e-physician.info/NPI-1922301803-MD
All contact information listed in financials, Univec website, pinksheets, and online search engine.
stockmaster
the labeler code PR had Daltons name on it and the Godaddy website is in Chaitra Dalton's name (isn't that his daughter). His name is all over this.
Administrative Contact:
Dalton, Chaitra chaitradalton@gmail.com
UNIVEC INC.
822 Guilford Ave.
Baltimore
Baltimore, Maryland 21202
United States
(410) 347-9959 Fax -- (410) 347-1542
stockmaster
let's say your correct and Dalton stepped away from this handing the assets off to Corey Ribotsky. If this is the case Univec, Inc is basically now worth nothing as Corey has been charged by the SEC and is probably looking at serious jail time. So Ribotsky is probably dumping it all and getting liquid as possible at this point. All in all smells like univec is done.
Maybe David Dalton is caught up in the whole Corey Ribotsky scandal and is trying to unload all is shares into cash and send it to his Cayman account before the authorities get him as well.. just my thoughts.
this dumping of shares at .0002 sucks, next .0001 then what no bid?
i don't even know if it's worth if to cost average into this at .0001 what if it hits no bid and Dalton keeps dumping shares
UNVC shareholders weep this holiday season, Dalton leaves us out in the cold while selling 150 Mill on the back end, welcome to the pinksheets.